Phase IV Proof of Efficacy: A Brilinta Idea?
This article was originally published in RPM Report
Executive Summary
AstraZeneca won two strong votes in favor of approval of its clot-busting drug Brilinta (ticagrelor) from FDA's Cardio-Renal Drugs Advisory Committee on July 28. Standing between the drug and final FDA approval, however, is an unusual request from the advisory committee for a supporting Phase IV efficacy study in the same indication as approval. That's a sign of the troublesome advice that FDA is getting on post-maketing studies form advisory committees.
You may also be interested in...
IoM Will Address Ethics in Safety Studies Prior To Avandia Advisory Committees
FDA is acting to create political and scientific cover for the second public review of Avandia safety issues in mid-July. A former top staffer to House Energy & Commerce Chairman Waxman is doing an internal study of agency post-marketing safety procedures to assure Capitol Hill that FDA takes the issue seriously; an IoM workshop is convening in early June to prepare a preliminary review on the ethical issues with post-market safety studies.
FDAAA Impact (Year Two): More of Everything
The second year of the FDAAA-era is over, and FDA is using its new drug safety tools (Risk Evaluation & Mitigation Strategies and mandatory post-marketing studies) more often. Not only are more drugs requiring REMS and mandatory trials, the burden of those programs is increasing.
The Prasugrel Backlash: Another Black Eye for FDA's Advisory Committee Process
FDA is the first to acknowledge that a lot of things went wrong during the run-up to the prasugrel advisory committee meeting, not the least of which is how the agency handles allegations of intellectual bias among its members. For drug sponsors, it may mean that the rules of engagement have changed.